Deep Brain Stimulation

Policy
The Medical Management Department reviews referral requests for authorization of deep brain stimulation.

This Medical Policy does not constitute medical advice. When deciding coverage, the enrollee’s specific plan document must be referenced. The terms of an enrollee’s plan document (Certificate of Coverage (COC) or Summary Plan Description (SPD)) may differ from this Medical Policy. In the event of a conflict, the enrollee’s specific benefit plan document supersedes this Medical Policy. All reviewers must first identify enrollee eligibility, any federal or state regulatory requirements, and the plan benefit coverage prior to use of this Medical Policy. Other Policies and Coverage Determination Guidelines may apply. Quartz reserves the right, in its sole discretion, to modify its Policies and Guidelines as necessary.

Procedure
A. Documentation Required:
To facilitate the authorization process referral requests must include ALL the following:
1. Documentation that a physician specializing in movement disorders or epilepsy as indicated is involved with selection of patients for deep brain stimulation treatment and post-procedure care.
2. Documentation of patient movement/neurologic symptoms, (e.g., tremor and degree of functional impairment and motor disability) using a tool to rate the level of disability, (e.g., Hoehn and Yahr stage, Unified Parkinson's disease rating scale (UPDRS) part 3 motor subscale or Fahn-Tolosa-Marin Clinical Tremor rating scale).
3. Documentation of seizure type and frequency, as indicated.
4. Documentation of failed treatments including medication trials and any adverse effects from medication trials.
5. Documentation of previous surgical procedures of the brain or implantation of nerve or brain stimulation devices.

B. Criteria for Medical Necessity:
1. Refractory motor complication of Parkinson’s disease: The placement of an implantable Deep Brain Stimulation device (i.e., stimulation of the globus pallidus internus or the subthalamic nucleus is considered medically necessary to treat patients with refractory motor complications of Parkinson’s disease when ALL the following are met:
   a. Persistent, disabling Parkinson’s disease symptoms despite optimal medical therapy that includes ≥ 12 weeks of carbidopa-levodopa treatment and a 12-week trial of at least ONE of the following medications unless optimal medical therapy is not tolerated due to medication side effects:
      i. Dopamine receptor agonist;
      ii. Monamine oxidase B inhibitor;
      iii. Catechol-o-methyltransferase (COMT) inhibitor;
      iv. Anticholinergic;
      v. Amantadine; AND
b. Minimum score of 30 points on the UPDRS motor examination scale; **AND**
c. Responsive to levodopa therapy with clearly defined “on” periods (e.g., levodopa challenge response positive); **AND**
d. Does not have dementia, severe depression or Hoehn and Yahr stage V Parkinson’s disease (unable to get out of bed or chair without help); **AND**
e. Presence of at least 2 major symptoms of Parkinsonism (e.g., tremor, rigidity, and bradykinesia); **AND**
f. Device is FDA approved.

2. **Intractable limb tremors:** The placement of an implantable Deep Brain Stimulation device (i.e., stimulation of the globus pallidus internus, the subthalamic nucleus, or ventral intermediate thalamic nucleus) in patients with intractable tremors is considered medically necessary when **ALL** the following are met:
   a. Persistent tremor that leads to a significant disability in activities of daily living despite ≥ 12-week trial of optimal medical therapy that includes at least two medications (e.g., beta-blocker, antiepileptic or Botulinum toxin A) unless optimal medical therapy is not tolerated due to medication side effects; **AND**
   b. Diagnosis of Essential Tremor or Parkinson’s disease as the cause of the tremor; **AND**
   c. Alternative causes of tremor that could explain the failure to respond to therapy have been explored and do not exist; **AND**
   d. Does not have dementia, severe depression or Hoehn and Yahr stage V Parkinson’s disease (unable to get out of bed or chair without help); **AND**
   e. Device is FDA approved.

3. **Dystonia:** The placement of an implantable Deep Brain Stimulation device (i.e., stimulation of the globus pallidus internus or the subthalamic nucleus), in patients with dystonia is considered medically necessary when **ALL** the following are met:
   a. Age 7 or older; **AND**
   b. Diagnosis of intractable primary dystonia, including generalized and/or segmental dystonia, hemidystonia and cervical dystonia; **AND**
   c. Dystonia leads to a significant disability in activities of daily living despite optimal medical therapy that includes ≥ 12-week trial of at least one medication (e.g., trihexyphenidyl, benzodiazepine, tetrabenazine, baclofen) unless optimal medical therapy is not tolerated due to medication side effects; **AND**
   d. Device is FDA approved for this condition and age.

4. **Intractable focal seizures:**
   A. The placement of a **responsive cortical stimulation/responsive neurostimulation (RNS) device (e.g., NeuroPace® RNS system)** in patients with seizure disorder is considered medical necessary when **ALL** the following are met:
      a. Age 18 years and older; **AND**
      b. Diagnosis of focal seizures (i.e., complex partial seizures, motor partial seizures, or secondarily generalized seizures) that have undergone diagnostic testing and that localized no more than two epileptogenic foci, **AND**
      c. Seizures are refractory to two or more antiepileptic medications, **AND**
      d. Patient has frequent seizures with 3 or more disabling seizures per month over the past 3 months, **AND**
      e. Patient has disabling seizures, (e.g., seizures impair functional ability or cause bodily injury); **AND**
f. Patient is expected to have improved quality of life and decreased seizure frequency with use; **AND**
g. Device is FDA approved.

**B. Deep brain stimulation of the anterior nucleus of thalamus** using an FDA approved device, e.g., Medtronic DBS for epilepsy in patients with seizure disorder is considered medically necessary when **ALL** the following are met:

a. Age 18 years or older; **AND**

b. Diagnosis of focal seizures (i.e., complex partial seizures, motor partial seizures, or secondarily generalized seizures) that have undergone diagnostic testing and that localized no more than two epileptogenic foci; **AND**

c. Seizures are refractory to trials of 3 or more antiepileptic medications; **AND**

d. Patient has frequent seizures with at least 6 per month over the past 3 months **AND**

e. No more than 10 seizures per day on average, **AND**

f. Patient does not have a progressive neurologic or medical disease causing the seizures (e.g., brain tumor or neurodegenerative disease) **OR** a history of psychogenic seizures; **AND**

g. Patient does not have a vagal nerve stimulator **OR** the device is planned to be removed at the time of the deep brain stimulator placement; **AND**

h. The patient is able to operate the device or has a caregiver who can assist them with operating the device; **AND**

i. Patient has been screened for depression and suicide risk and does not have severe depression or untreated depression; **AND**

j. Patient is not pregnant.

**C. Indications Considered Experimental, Investigational or not Medically Necessary (Not an all-inclusive list):**


2. First line treatment for Parkinson’s disease or Essential Tremor.

3. Movement disorder symptoms (e.g., tremor), that adequately respond to medication without significant adverse effects.

4. Patient has significant cognitive impairment, dementia, severe depression, or Hoehn and Yahr stage V Parkinson’s disease that could be worsened by or would interfere with the patient’s ability to benefit from deep brain stimulation.

5. Patients with prior movement disorder surgery within the affected basal ganglion.

6. Implantation of a non-FDA approved DBS device.

**CPT/HCPCS CODES:**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>61863</td>
<td>Twist drill, burr hole, craniotomy, or craniectomy with stereotactic implantation of neurostimulator electrode array in subcortical site (e.g., thalamus, globus pallidus, subthalamic nucleus, periventricular, periaqueductal gray), without use of intraoperative microelectrode recording; first array</td>
</tr>
<tr>
<td>61864</td>
<td>each additional array (List separately in addition to primary procedure)</td>
</tr>
<tr>
<td>61867</td>
<td>Twist drill, burr hole, craniotomy, or craniectomy with stereotactic implantation of neurostimulator electrode array in subcortical site (e.g., thalamus, globus pallidus, subthalamic nucleus, periventricular,</td>
</tr>
</tbody>
</table>
periaqueductal gray), with use of intraoperative microelectrode recording; first array

61885 Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to a single electrode array

61886 with connection to 2 or more electrode arrays

95971 simple spinal cord, or peripheral (i.e., peripheral nerve, sacral nerve, neuromuscular) neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming

95974 complex cranial nerve neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming, with or without nerve interface testing, first hour

C1767 Generator, neurostimulator (implantable), nonrechargeable
C1778 Lead, neurostimulator (implantable)
C1816 Receiver and/or transmitter, neurostimulator (implantable)
C1883 Adaptor/extension, pacing lead or neurostimulator lead (implantable)
C1897 Lead, neurostimulator test kit (implantable)
E0745 Neuromuscular stimulator, electronic shock unit
L8680 Implantable neurostimulator electrode, each
L8681 Patient programmer (external) for use with implantable programmable neurostimulator pulse generator, replacement only
L8682 Implantable neurostimulator radiofrequency receiver
L8683 Radiofrequency transmitter (external) for use with implantable neurostimulator radiofrequency receiver
L8685 Implantable neurostimulator pulse generator, single array, rechargeable, includes extension
L8686 Implantable neurostimulator pulse generator, single array, non-rechargeable, includes extension
L8687 Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension
L8688 Implantable neurostimulator pulse generator, dual array, non-rechargeable, includes extension

References:


